

**United States Food and Drug Administration**

**Center for Drug Evaluation and Research**

**Division of Metabolic and Endocrine Drug Products**

**Advisory Committee**

**The Women's Health Initiative: Implications for Postmenopausal  
Hormone Therapy with Estrogen/Progestin in Women for the  
Prevention and Treatment of Osteoporosis.**

**Tuesday, October 7, 2003**